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Abstract Nicotinamide mononucleotide adenylyl transferase
(NMNAT) is an essential enzyme in all organisms, because it
catalyzes a key step of NAD synthesis. However, little is known
about the structure and regulation of this enzyme. In this study
we established the primary structure of human NMNAT. The
human sequence represents the first report of the primary
structure of this enzyme for an organism higher than yeast. The
enzyme was purified from human placenta and internal peptide
sequences determined. Analysis of human DNA sequence data
then permitted the cloning of a cDNA encoding this enzyme.
Recombinant NMNAT exhibited catalytic properties similar to
the originally purified enzyme. Human NMNAT (molecular
weight 31 932) consists of 279 amino acids and exhibits
substantial structural differences to the enzymes from lower
organisms. A putative nuclear localization signal was confirmed
by immunofluorescence studies. NMNAT strongly inhibited
recombinant human poly(ADP-ribose) polymerase 1, however,
NMNAT was not modified by poly(ADP-ribose). NMNAT
appears to be a substrate of nuclear kinases and contains at least
three potential phosphorylation sites. Endogenous and recombi-
nant NMNAT were phosphorylated in nuclear extracts in the
presence of [Q-32P]ATP. We propose that NMNAT’s activity or
interaction with nuclear proteins are likely to be modulated by
phosphorylation. ß 2001 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
The role of NAD as a coenzyme in cellular redox reactions
has long been recognized. In this function NAD represents an
essential component of metabolic pathways in all living cells.
Numerous recent studies have demonstrated the importance
of NAD as both metabolite and signaling molecule. For ex-
ample, high levels of NAD are required for life-span extension
in yeast mediated by the transcriptional silencing protein
Sir2p [1,2]. It has become apparent that NAD also partici-
pates in a number of other signaling pathways. These reac-
tions include monoADP-ribosylation, poly(ADP-ribosyl)-
ation, and the synthesis of calcium-mobilizing molecules
such as cyclic ADP-ribose and nicotinate adenine dinucleotide
phosphate (NAADP) which require NAD as a precursor (re-
viewed in [3]). NAD-dependent signaling routes have been
detected in several compartments including the cell surface.
However, poly(ADP-ribosyl)ation appears to be restricted to
the nucleus. The best characterized enzyme catalyzing this
process, poly(ADP-ribose) polymerase (PARP1), is involved
in a number of nuclear processes and has been established to
be a component of the DNA base excision repair complex [4].
It is clear that the synthesis of NAD and its regulation have
signi¢cant impact on both metabolism and signaling events
within the cell. The principal pathways of de novo and salvage
syntheses of NAD are well known. For example, essential
reactions in both the de novo and the salvage pathways are
catalyzed by nicotinamide mononucleotide adenylyl transfer-
ase (NMNAT) (EC 2.7.7.1). This enzyme transfers the ade-
nylyl moiety of ATP to NMN resulting in the formation of
NAD and the release of pyrophosphate. As this reaction is
reversible, the enzyme may in principle be used to form ATP
(and NMN) from NAD and pyrophosphate [5]. However, it is
surprising that so little is known about the structure and reg-
ulation of several enzymes that are crucial for pyridine nucle-
otide synthesis (e.g. NMNAT, NAD kinase).
NMNAT appears to be localized to the nucleus [6] and its
activity has been reported to correlate with DNA synthesis
during the cell cycle [7]. The enzyme could be a potential
target for therapeutical applications, because its activity is
rather low in tumor cells [8,9]. The protein has been proposed
to be associated with PARP1 [10,11]. This suggestion may
point to an important mechanism regulating NAD supply
during genotoxic challenges. Under such conditions PARP1
may consume a large fraction of the cellular NAD to form
poly(ADP-ribose) [12,13], a reaction considered most impor-
tant for e⁄cient DNA repair [14,15]. Since in these situations
the ATP concentration is also lowered, the resynthesis of
NAD is a¡ected. Therefore, inhibition of PARP1 by
NMNAT would counteract the loss of NAD.
Although several mammalian NMNATs have been puri¢ed
[5], to date the primary structures have only been reported for
enzymes from microorganisms such as Saccharomyces cerevi-
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siae [16], Methanococcus jannaschii [17], Synechocystis sp. [18],
and Escherichia coli [19].
In this study the primary structure of the human NMNAT
has been established. The identity of the enzyme was veri¢ed
by expression of the recombinant protein in E. coli and the
nuclear localization of the protein was demonstrated in hu-
man cell lines. Recombinant NMNAT exerted a strong inhib-
itory e¡ect on recombinant human PARP1. Moreover,
NMNAT was demonstrated to be phosphorylated in nuclear
extracts and therefore, besides its function as an enzyme,
NMNAT can be implicated in regulatory processes as well.
2. Materials and methods
2.1. Puri¢cation of human NMNAT
Puri¢cation of NMNAT was performed according to the procedure
described by Magni et al. [20]. Brie£y, the isolation of the enzyme
from human placenta involved a pH precipitation (at pH 5) and
chromatography using adsorption and a⁄nity resins including phe-
nyl-Sepharose, matrix gel green A and hydroxyapatite. The ¢nal pu-
ri¢cation step was carried out using a TSKgel phenyl 5PW column
(TosoHaas) on an FPLC system (BioLogic, Bio-Rad). The pooled
fractions were concentrated and stored at 4‡C in a bu¡er containing
50 mM potassium phosphate, pH 7.4, 1 mM dithiothreitol, 1 mM
MgCl2, 0.5 mM EDTA, and 300 mM KCl (NMNAT bu¡er).
All puri¢cation steps were monitored by sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE). Protein concentra-
tion was estimated using the BCA assay (Pierce) with bovine serum
albumin (BSA) as standard.
2.2. Enzyme assay
Activity of NMNAT (synthesis of NAD) was measured in a
coupled enzyme assay by monitoring the increase in absorbance at
340 nm caused by the reduction of NAD to NADH. The reaction was
performed in 16 mM semicarbacide^HCl, 0.625% (v/v) ethanol, 30
mM HEPES bu¡er (pH 7.4), 12.25 mM MgCl2, 1.17 mM ATP,
15 U alcohol dehydrogenase (Sigma), and started by adding NMN
to a ¢nal concentration of 0.625 mM.
The reverse reaction (using NAD and pyrophosphate as substrates)
and the ability of NMNAT to utilize substrate analogs were deter-
mined by metabolite analysis using an anion exchange column
(MonoQ, Pharmacia). For quanti¢cation, [32P]NAD or [K-32P]ATP
were used. Metabolites were separated by thin layer chromatography
and quanti¢ed with the aid of a phosphoimager.
2.3. Peptide sequencing
The isolated protein was run on SDS^PAGE to separate it from
residual contaminating proteins. Following staining with Coomassie
blue the band corresponding to an apparent molecular weight of
33 000 was excised and subjected to ‘in gel’ digestion by trypsin
[21]. The resulting peptides were separated by reverse-phase high per-
formance liquid chromatography (HPLC) on a Vydac C18 column
(4.6U250 mm) using a Waters 626 liquid chromatography HPLC
system (Waters, Milford, MA, USA). The peptides were eluted in a
gradient from 0.1% (v/v) tri£uoroacetic acid in water to 0.085% (v/v)
tri£uoroacetic acid in acetonitrile.
Amino acid sequences were obtained from puri¢ed peptide fractions
by Edman degradation or by matrix-assisted laser desorption/ioniza-
tion-time of £ight (MALDI-TOF) mass spectrometry (Bruker Re£ex
mass spectrometer) via analysis of fragment ions generated by post-
source decay [22], using the FAST1 method (Bruker).
2.4. Reverse transcription PCR
Cytoplasmic RNA from lymphoblastoid cells was isolated as de-
scribed in [23]. Reverse transcription of 3 Wg of RNA was performed
in RT bu¡er (Promega) containing 250 WM dNTP, 40 U RNase in-
hibitor (Life Technologies), and 140 U M-MLV reverse transcriptase
(Promega) in a total volume of 30 Wl at 37‡C for 1 h. Following
cDNA synthesis RNA was digested by adding 40 U RNase H (Ta-
kara). cDNA ampli¢cation was carried out in PCR bu¡er (Perkin-
Elmer) containing 125 WM dNTP, 1.5 mM MgCl2, 20 pmol of each
primer, and 1.5 U Taq Polymerase (Perkin-Elmer). The primers for
ampli¢cation of NMNAT cDNA were 5P-CTT TGG ATC CGA
AAA TTC CGA GAA GAC TGA-3P and 5P-CCA CAA GCT TCT
ATG TCT TAG CTT CTG CAG-3P.
2.5. Expression cloning
PCR products were ligated into the TOPO 2.1 vector (Invitrogen)
and transfected into E. coli according to the manufacturer’s protocol.
NMNAT cDNA was subcloned into the pQE30 vector (Qiagen) via
the BamHI and HindIII sites and the vector construct was transfected
into E. coli (NM 522) cells. Recognition sites for the restriction en-
zymes were included into the PCR primer sequences. The resulting
recombinant protein carried a ‘6UHis’-tag at the N-terminus for sub-
sequent puri¢cation.
2.6. Expression and puri¢cation of recombinant human NMNAT
An overnight culture was transferred into 1 l of TY medium sup-
plemented with 100 Wg/ml ampicillin. At an optical density of 0.6 at
600 nm of the bacteria culture expression was induced by adding
isopropyl-L-thiogalactopyranoside to a ¢nal concentration of 2 mM.
Following 4 h of expression the bacteria were harvested by centri-
fugation. Cells were sonicated and the lysate was applied to a nickel-
nitrilotriacetic acid column. The column was washed and eluted with
imidazole according to the manufacturer’s protocol (Qiagen). The
puri¢cation yielded almost homogenous (6 5% contaminating pro-
tein) recombinant NMNAT.
2.7. Cell culture and immuno£uorescence analyses
Puri¢ed recombinant human NMNAT was used as antigen for the
generation of a rabbit antiserum. NMNAT-speci¢c antibodies were
extracted from the serum as follows. Recombinant NMNAT was
coupled to CNBr-Sepharose (Sigma). The antiserum was incubated
with the resin for 1 h. After several washes the antibodies were eluted
with 300 mM glycine^HCl, pH 2.8 and 300 mM NaCl. The pH of the
eluate was immediately adjusted with Tris to pH 7^7.5 and glycerol
was added to 20% (v/v).
Human cell lines (HeLa, HepG2, primary and transformed ¢bro-
blast cell lines) were grown on cover slips and ¢xed with paraformal-
dehyde. Following successive incubation with the NMNAT-speci¢c
antibodies and £uorescein-labeled anti-rabbit IgG the presence of
NMNAT in the cells was visualized using a Leica £uorescence micro-
scope. For staining of the transcription factor YY1 a monoclonal
antibody was used (H-10, Santa Cruz). The second antibody was an
anti-mouse IgG from goat coupled with rhodamine.
2.8. Poly(ADP-ribosyl)ation assay
Human recombinant PARP1 (300 ng) was incubated in the absence
or presence of recombinant NMNAT (300 ng) in a bu¡er containing
10 mM Tris^HCl, pH 8.0, 7 mM MgCl2, 50 mM ZnCl2, 1% BSA, 10
Wg/ml sonicated salmon sperm DNA, and 5 nM [32P]NAD. After 10
min aliquots were withdrawn and precipitated with trichloroacetic
acid (TCA, 10% w/v). To the remaining sample 10 WM of unlabeled
NAD was added and the reaction continued for 10 min. Thereafter,
the samples were stopped by TCA precipitation. Proteins were sepa-
rated by 10% SDS^PAGE and poly(ADP-ribosyl)ation visualized by
autoradiography. In parallel experiments the incorporation of poly-
(ADP-ribose) was quanti¢ed by Cerenkov counting.
2.9. Protein phosphorylation assay
Nuclear extracts were prepared from human ¢broblasts according
to [24]. The extracts (20 Wg of protein) were incubated at 30‡C with
100 WM [Q-32P]ATP (NEN DuPont) in the presence or absence of 10
Wg of recombinant NMNAT in a bu¡er consisting of 10 mM HEPES-
KOH, pH 7.9, 7 mM MgCl2, 50 mM KCl, 100 mM NaCl, 0.1 mM
EDTA, 0.25 mM dithiothreitol, and 10% (v/v) glycerol. Following
incubation for 30 min the reaction was stopped and the samples sub-
jected to SDS^PAGE. If no recombinant NMNAT was added to the
incubations, after 30 min immunoprecipitation of the endogenous
NMNAT was conducted using the polyclonal antibodies and protein
A Sepharose. Phosphorylated proteins were detected by autoradiog-
raphy following SDS^PAGE.
3. Results
NMNAT was puri¢ed from human placenta and the en-
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zyme preparation was analyzed by SDS^PAGE (Fig. 1, left
lane). The gel electrophoresis resulted in a prominent protein
band of about 33 kDa, well separated from a few minor
protein bands. Since it has been reported that the subunit
molecular mass of human NMNAT is about 33 kDa [25],
this band was excised from the gel and subjected to ‘in gel’
digestion with trypsin [21]. The sequences of two resulting
peptides were established to be SNIHVVNEWIANDISSTK
and NAGVILAPLQR using both MALDI-TOF and auto-
mated microsequencing. These sequences were compared to
protein and nucleic acid sequences deposited in available data-
bases. Coding sequences for both peptides were found in the
GenBank database as part of an EST (EST 182517, GenBank
accession number AA311657). According to this sequence the
two peptides would be located in the protein only 37 amino
acids apart from each other. When the NMNAT cDNA se-
quence was eventually established (see below), it turned out
that this EST indeed contains the coding region for the 72 C-
terminal amino acids of NMNAT. Moreover, a potential cod-
ing region for the ¢rst peptide was also found in the sequence
of another EST (EST 601141175F1, GenBank accession num-
ber BE272001). This EST covers nucleotides 92^759 of the
cDNA sequence established in this study. The 5P-terminal se-
quence of the NMNAT cDNA could be deduced from an
EST (EST qh84c06.U1, GenBank accession number
AI243824) which contains the coding region of NMNAT up
to nucleotide 353 and overlaps with EST 601141175F1 in a
stretch of 260 nucleotides. Aligning the three overlapping
ESTs an open reading frame was deduced that could poten-
tially encode human NMNAT.
Fig. 1. Gel electrophoretic separation of NMNAT. NMNAT was
puri¢ed from human placenta (left lane) or from overexpression in
E. coli (right lane) as described in Section 2. SDS^PAGE was per-
formed using a 12.5% acrylamide gel. Proteins were stained with
Coomassie blue. Numbers on the left indicate the mobility of
marker proteins.
Fig. 2. Complete coding sequence of the human NMNAT cDNA and the deduced amino acid sequence. Gray boxes highlight the two peptides
initially determined (amino acids 208^225 and 262^272). A putative nuclear localization signal (NLS) is indicated (amino acids 123^129). Ser-
ines 109, 136, and 256 are typed in bold face, because they represent potential phosphorylation sites (probability score s 0.98). The GenBank
accession number of the sequence is AF314163.
FEBS 24626 5-3-01
M. Schweiger et al./FEBS Letters 492 (2001) 95^100 97
This information was used to clone the cDNA encoding
NMNAT. PCR was carried out using primers corresponding
to the presumed 5P- and 3P-terminal sequences and a cDNA
library prepared from human lymphoblastoid cells. The am-
pli¢ed DNA had the expected size of approximately 850 bp.
Sequencing revealed that the ampli¢ed cDNA indeed con-
tained two internal sequence stretches that would encode the
previously established peptides. Moreover, the sequences of
the ESTs were almost identical to the corresponding parts
of the ampli¢ed cDNA. The sequence of the 5P-upstream re-
gion of the cDNA was veri¢ed to ensure the correct prediction
of the open reading frame. Eventually, the putative coding
region was cloned into the pQE vector in order to attach an
N-terminal 6UHis-tag to the protein.
The recombinant protein was then overexpressed in E. coli
and puri¢ed (Fig. 1, lane 2). The speci¢c activity of the puri-
¢ed recombinant enzyme amounted to about 25 U/mg of pro-
tein. The properties of this protein were virtually identical to
those found for NMNAT puri¢ed from human placenta [25].
In Fig. 2 the complete DNA sequence corresponding to the
coding region of the mRNA of human NMNAT is shown
along with the deduced amino acid sequence. The two tryptic
peptides initially sequenced are indicated. Both peptides
matched fully with the deduced amino acid sequence.
The human NMNAT consists of 279 amino acids and has a
theoretical molecular mass of 31 932 Da. This molecular mass
is in good agreement with that estimated for the puri¢ed pro-
tein in this (Fig. 1) and previous studies [20,25].
Comparison to the amino acid sequence of the yeast en-
zyme [16] revealed that the human form lacks the region of
the ¢rst 197 N-terminal amino acids, similar to the putative
NMNATs from Caenorhabditis elegans [16]. This is in accor-
dance with the di¡erence in subunit molecular masses (48 kDa
and 32 kDa for the yeast and human enzymes, respectively).
The C-terminal part of the yeast protein (corresponding to the
complete human sequence) displays about 38% identity to the
human enzyme.
Analysis of the primary structure of the human NMNAT
by the PSORT II program revealed the presence of a putative
nuclear localization signal (PGRKRKW, amino acids 123^
129, cf. Fig. 2). The nuclear localization of this enzyme was
clearly demonstrated by immuno£uorescence (Fig. 3). An af-
¢nity-puri¢ed rabbit antibody raised against the recombinant
NMNAT was highly speci¢c for NMNAT as revealed by
Western blot analysis conducted with lysates of HepG2
(Fig. 3F) and other cells (HeLa, ¢broblasts, not shown). Im-
Fig. 3. Immuno£uorescent subcellular localization of the human NMNAT. Human ¢broblasts (A and B) or HepG2 cells (C^E) were immuno-
stained with a puri¢ed polyclonal NMNAT antibody raised in rabbit (A and C). B: Phase contrast image. D: Chromosomal stain with DAPI.
E: Immuno£uorescence of transcription factor YY1 was used as an additional control for nuclear staining. F shows a Western blot of HepG2
cell lysates developed with the puri¢ed NMNAT antibody. Numbers on the right indicate the mobility of prestained marker proteins.
Fig. 4. In£uence of recombinant NMNAT on the activity of
PARP1. Recombinant human PARP1 was incubated with [32P]NAD
in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of re-
combinant human NMNAT under the conditions described in Sec-
tion 2. At low concentrations of [32P]NAD (5 nM, lanes 1 and 2)
only short ADP-ribose oligomers are formed (1^7 units). Addition
of 10 WM of unlabeled NAD to the samples presented in lanes 1
and 2 led to the formation of long ADP-ribose polymers and a con-
comitant shift of PARP1’s apparent molecular mass (lanes 3 and 4).
A long stacking gel was used to demonstrate the inability of a sig-
ni¢cant fraction of PARP1 to enter the gel indicating the formation
of branched polymers (lane 3) which was not observed in the pres-
ence of NMNAT (lane 4). The autoradiogram of a representative
gel is shown.
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munostaining of primary human ¢broblasts (Fig. 3A,B) and
HepG2 cells (Fig. 3C^E) demonstrated the presence of
NMNAT in the nuclei. The assignment of the nucleus was
based on costaining of the transcription factor YY1 (Fig.
3D) and staining of the chromosomes by 4P,6-diamidino-2-
phenylindole (DAPI) (Fig. 3E). Nuclear localization of
NMNAT was also observed in HeLa cells (not shown).
It has been proposed [10,11] that NMNAT may interact
with the nuclear protein PARP1. Using both recombinant
human enzymes the in£uence of NMNAT on PARP1 activity
was tested. As shown in Fig. 4 NMNAT substantially reduced
the automodi¢cation of PARP1. Moreover, NMNAT did not
serve as acceptor protein of the modi¢cation (lane 2). Quan-
ti¢cation of automodi¢cation of PARP1 established that the
presence of NMNAT led to a decrease to about 35%.
NMNAT appeared to completely prevent the formation of
branched ADP-ribose polymers.
According to a previous report [25] the enzyme isolated
from human placenta exhibited several acidic isoelectric
points (pH 4.7, 5.7, and 6.6). However, if calculated from
the amino acid composition found here, the isoelectric point
would be at pH 8.98. This discrepancy could be, at least in
part, due to post-translational modi¢cations such as phos-
phorylation. Indeed, an analysis using the NetPhos 2.0 pro-
gram strongly indicated the presence of potential phosphory-
lation sites (Fig. 2). The probability score for three serine
residues (amino acids 109, 136, and 256, cf. Fig. 2) exceeded
0.98. It was tested, therefore, whether NMNAT serves as sub-
strate for nuclear kinases. Incubation of the recombinant
NMNAT with nuclear extracts in the presence of [Q-32P]ATP
led to substantial labeling of the enzyme (Fig. 5A). The label
was removed by incubation with alkaline phosphatase sup-
porting the conclusion that NMNAT is a substrate for phos-
phorylation. This notion was further substantiated by incu-
bating nuclear extracts in the presence of [Q-32P]ATP and
subsequent immunoprecipitation of endogenous NMNAT us-
ing a puri¢ed polyclonal antibody generated against the re-
combinant enzyme (cf. Fig. 3F). As shown in Fig. 5B, the
majority of phosphorylated proteins were not precipitated
(lane 1), whereas a precipitated radiolabeled protein migrated
corresponding to NMNAT (lane 2). An unidenti¢ed phos-
phorylated protein of approximately 36 kDa appeared to spe-
ci¢cally coprecipitate with NMNAT (Fig. 5B, lane 2). It can-
not be ruled out, however, that this band represents a
hyperphosphorylated form of NMNAT.
4. Discussion
The identi¢cation of the primary structure of human
NMNAT represents a major step towards the understanding
of pyridine nucleotide biosynthesis. It is the ¢rst established
sequence of NMNAT from an organism higher than yeast. All
known pathways leading to the synthesis of NAD require
NMNAT. Therefore, this enzyme is of crucial importance
for metabolism, energy supply and signal transduction.
Although the enzyme would be expected to be highly con-
served, because it must be present in all organisms, there
are substantial di¡erences to the counterparts in lower organ-
isms. For example, the yeast enzyme contains an amino-ter-
minal stretch of 179 amino acids which is completely absent
from the human enzyme. Nevertheless, the catalytic properties
of the two forms are very similar. Possibly, variations in the
primary structure may be related to mechanisms regulating
the catalytic activity or interactions with other proteins. Com-
paring the sequence of the human NMNAT (279 amino acids)
to that of M. jannaschii (168 amino acids) revealed only very
weak similarities in short sequence stretches.
Investigations over the past years have added further weight
to the essential role of the pyridine coenzymes. The role of
NAD as precursor of signaling molecules and as substrate for
protein modi¢cation underlines the importance of the regula-
tion of NAD synthesis. In this regard it is intriguing that
NMNAT is located within the nucleus as clearly demon-
strated in this study. It is also an important ¢nding that
NMNAT appears to be a substrate for nuclear kinase(s).
The immunoprecipitation conducted in this study indicated
that phosphorylated NMNAT is in a complex with at least
one other phosphorylated protein. A speci¢c interaction be-
tween recombinant human NMNAT and PARP1 has been
found in this study by demonstrating a signi¢cant inhibition
of automodi¢cation of PARP1 in the presence of NMNAT
(Fig. 4). An essential role has been ascribed to NMNAT in
the cellular response to genotoxic damage. Under these con-
ditions PARP1 may consume most of the cellular NAD. The
decrease of the ATP concentration has been proposed to be a
result of the resynthesis of NAD which requires ATP [26].
Consequently, inhibition of PARP1 by NMNAT may be di-
rected to prevent NAD and ATP depletion.
In addition to its essential role in NAD synthesis, NMNAT
could also be important for the synthesis of the NADP de-
rivative, NAADP. This nucleotide has been demonstrated to
be a highly potent calcium-mobilizing agent (reviewed in [27]).
A potential synthetic pathway could include the synthesis of
Fig. 5. Phosphorylation of endogenous and recombinant NMNAT
in nuclear extracts. Nuclear extracts were prepared from human ¢-
broblasts (cf. Fig. 3) and incubated for 30 min at 30‡C with [Q-
32P]ATP in the presence (A) or absence (B) of recombinant
NMNAT as described in Section 2. A: Following incubation an ali-
quot was withdrawn (lane 1). The remainder was supplemented with
2 U of alkaline phosphatase and incubated for another 30 min (lane
2). B: Following incubation, immunoprecipitation of endogenous
NMNAT was conducted using the puri¢ed antibody and protein A
Sepharose (see Section 2). Unbound protein (lane 1) was removed,
the Sepharose washed thoroughly and speci¢cally bound proteins
(lane 2) were eluted. Samples were separated in a 12% SDS^polyac-
rylamide gel and phosphorylated proteins visualized by autoradiog-
raphy. The arrows indicate the positions of recombinant or endoge-
nous NMNAT, respectively.
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NAAD from nicotinic acid mononucleotide and ATP by
NMNAT followed by phosphorylation by NAD kinase or a
similar enzyme. In conclusion, the present study suggests that
NMNAT is likely to be more than a simple metabolic enzyme,
because it is located exclusively within the nucleus, exhibits
speci¢c interactions with PARP1 and appears to be regulated
by phosphorylation.
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